Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer

Jair Machado Espindola-Netto, Claudia C.S. Chini, Mariana Tarragó, Enfeng Wang, Shamit Dutta, Krishnendu Pal, Debabrata Mukhopadhyay, Mauro Sola-Penna, Eduardo Nunes Chini

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

NAD salvage is one of the pathways used to generate NAD in mammals. Nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in this pathway, uses nicotinamide (NAM) to generate nicotinamide mononucleotide (NMN). NMN is one of the main precursors of NAD synthesis in cells. Our previous study showed the importance of NAMPT in maintaining NAD levels in pancreatic ductal adenocarcinoma cells (PDAC), and that the NAMPT inhibitor FK866 decreased pancreatic cancer growth. We now tested the effect of STF-118804, a new highly specific NAMPT inhibitor, in models of pancreatic ductal adenocarcinoma. STF-118804 reduced viability and growth of different PDAC lines, as well as the formation of colonies in soft agar. In addition, STF-118804 decreased glucose uptake, lactate excretion, and ATP levels, resulting in metabolic collapse. STF-118804 treatment activated AMPK and inhibited of mTOR pathways in these cells. This effect was significantly potentiated by pharmacological AMPK activation and mTOR inhibition. Exogenous NMN blocked both the activation of the AMPK pathway and the decrease in cell viability. Panc-1 cells expressing GFP-luciferase were orthotopically implanted on mice pancreas to test the in vivo effectiveness of STF-118804. Both STF-118804 and FK866 reduced tumor size after 21 days of treatment. Combinations of STF- 118804 with chemotherapeutic agents such as paclitaxel, gemcitabine, and etoposide showed an additive effect in decreasing cell viability and growth. In conclusion, our preclinical study shows that the NAMPT inhibitor STF-118804 reduced the growth of PDAC in vitro and in vivo and had an additive effect in combination with main current chemotherapeutic drugs.

Original languageEnglish (US)
Pages (from-to)85054-85067
Number of pages14
JournalOncotarget
Volume8
Issue number49
DOIs
StatePublished - Oct 17 2017

Fingerprint

Nicotinamide Phosphoribosyltransferase
Pancreatic Neoplasms
Nicotinamide Mononucleotide
NAD
AMP-Activated Protein Kinases
Adenocarcinoma
Growth
gemcitabine
Cell Survival
Niacinamide
STF-118804
Etoposide
Paclitaxel
Luciferases
Agar
Pancreas
Mammals
Lactic Acid
Adenosine Triphosphate
Pharmacology

Keywords

  • Metabolism
  • NAD
  • NAMPT
  • Pancraetic cancer
  • STF-11804

ASJC Scopus subject areas

  • Oncology

Cite this

Espindola-Netto, J. M., Chini, C. C. S., Tarragó, M., Wang, E., Dutta, S., Pal, K., ... Chini, E. N. (2017). Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer. Oncotarget, 8(49), 85054-85067. https://doi.org/10.18632/oncotarget.18841

Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer. / Espindola-Netto, Jair Machado; Chini, Claudia C.S.; Tarragó, Mariana; Wang, Enfeng; Dutta, Shamit; Pal, Krishnendu; Mukhopadhyay, Debabrata; Sola-Penna, Mauro; Chini, Eduardo Nunes.

In: Oncotarget, Vol. 8, No. 49, 17.10.2017, p. 85054-85067.

Research output: Contribution to journalArticle

Espindola-Netto, JM, Chini, CCS, Tarragó, M, Wang, E, Dutta, S, Pal, K, Mukhopadhyay, D, Sola-Penna, M & Chini, EN 2017, 'Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer', Oncotarget, vol. 8, no. 49, pp. 85054-85067. https://doi.org/10.18632/oncotarget.18841
Espindola-Netto JM, Chini CCS, Tarragó M, Wang E, Dutta S, Pal K et al. Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer. Oncotarget. 2017 Oct 17;8(49):85054-85067. https://doi.org/10.18632/oncotarget.18841
Espindola-Netto, Jair Machado ; Chini, Claudia C.S. ; Tarragó, Mariana ; Wang, Enfeng ; Dutta, Shamit ; Pal, Krishnendu ; Mukhopadhyay, Debabrata ; Sola-Penna, Mauro ; Chini, Eduardo Nunes. / Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer. In: Oncotarget. 2017 ; Vol. 8, No. 49. pp. 85054-85067.
@article{449b48cad8764d8b90aca3f964916739,
title = "Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer",
abstract = "NAD salvage is one of the pathways used to generate NAD in mammals. Nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in this pathway, uses nicotinamide (NAM) to generate nicotinamide mononucleotide (NMN). NMN is one of the main precursors of NAD synthesis in cells. Our previous study showed the importance of NAMPT in maintaining NAD levels in pancreatic ductal adenocarcinoma cells (PDAC), and that the NAMPT inhibitor FK866 decreased pancreatic cancer growth. We now tested the effect of STF-118804, a new highly specific NAMPT inhibitor, in models of pancreatic ductal adenocarcinoma. STF-118804 reduced viability and growth of different PDAC lines, as well as the formation of colonies in soft agar. In addition, STF-118804 decreased glucose uptake, lactate excretion, and ATP levels, resulting in metabolic collapse. STF-118804 treatment activated AMPK and inhibited of mTOR pathways in these cells. This effect was significantly potentiated by pharmacological AMPK activation and mTOR inhibition. Exogenous NMN blocked both the activation of the AMPK pathway and the decrease in cell viability. Panc-1 cells expressing GFP-luciferase were orthotopically implanted on mice pancreas to test the in vivo effectiveness of STF-118804. Both STF-118804 and FK866 reduced tumor size after 21 days of treatment. Combinations of STF- 118804 with chemotherapeutic agents such as paclitaxel, gemcitabine, and etoposide showed an additive effect in decreasing cell viability and growth. In conclusion, our preclinical study shows that the NAMPT inhibitor STF-118804 reduced the growth of PDAC in vitro and in vivo and had an additive effect in combination with main current chemotherapeutic drugs.",
keywords = "Metabolism, NAD, NAMPT, Pancraetic cancer, STF-11804",
author = "Espindola-Netto, {Jair Machado} and Chini, {Claudia C.S.} and Mariana Tarrag{\'o} and Enfeng Wang and Shamit Dutta and Krishnendu Pal and Debabrata Mukhopadhyay and Mauro Sola-Penna and Chini, {Eduardo Nunes}",
year = "2017",
month = "10",
day = "17",
doi = "10.18632/oncotarget.18841",
language = "English (US)",
volume = "8",
pages = "85054--85067",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "49",

}

TY - JOUR

T1 - Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer

AU - Espindola-Netto, Jair Machado

AU - Chini, Claudia C.S.

AU - Tarragó, Mariana

AU - Wang, Enfeng

AU - Dutta, Shamit

AU - Pal, Krishnendu

AU - Mukhopadhyay, Debabrata

AU - Sola-Penna, Mauro

AU - Chini, Eduardo Nunes

PY - 2017/10/17

Y1 - 2017/10/17

N2 - NAD salvage is one of the pathways used to generate NAD in mammals. Nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in this pathway, uses nicotinamide (NAM) to generate nicotinamide mononucleotide (NMN). NMN is one of the main precursors of NAD synthesis in cells. Our previous study showed the importance of NAMPT in maintaining NAD levels in pancreatic ductal adenocarcinoma cells (PDAC), and that the NAMPT inhibitor FK866 decreased pancreatic cancer growth. We now tested the effect of STF-118804, a new highly specific NAMPT inhibitor, in models of pancreatic ductal adenocarcinoma. STF-118804 reduced viability and growth of different PDAC lines, as well as the formation of colonies in soft agar. In addition, STF-118804 decreased glucose uptake, lactate excretion, and ATP levels, resulting in metabolic collapse. STF-118804 treatment activated AMPK and inhibited of mTOR pathways in these cells. This effect was significantly potentiated by pharmacological AMPK activation and mTOR inhibition. Exogenous NMN blocked both the activation of the AMPK pathway and the decrease in cell viability. Panc-1 cells expressing GFP-luciferase were orthotopically implanted on mice pancreas to test the in vivo effectiveness of STF-118804. Both STF-118804 and FK866 reduced tumor size after 21 days of treatment. Combinations of STF- 118804 with chemotherapeutic agents such as paclitaxel, gemcitabine, and etoposide showed an additive effect in decreasing cell viability and growth. In conclusion, our preclinical study shows that the NAMPT inhibitor STF-118804 reduced the growth of PDAC in vitro and in vivo and had an additive effect in combination with main current chemotherapeutic drugs.

AB - NAD salvage is one of the pathways used to generate NAD in mammals. Nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in this pathway, uses nicotinamide (NAM) to generate nicotinamide mononucleotide (NMN). NMN is one of the main precursors of NAD synthesis in cells. Our previous study showed the importance of NAMPT in maintaining NAD levels in pancreatic ductal adenocarcinoma cells (PDAC), and that the NAMPT inhibitor FK866 decreased pancreatic cancer growth. We now tested the effect of STF-118804, a new highly specific NAMPT inhibitor, in models of pancreatic ductal adenocarcinoma. STF-118804 reduced viability and growth of different PDAC lines, as well as the formation of colonies in soft agar. In addition, STF-118804 decreased glucose uptake, lactate excretion, and ATP levels, resulting in metabolic collapse. STF-118804 treatment activated AMPK and inhibited of mTOR pathways in these cells. This effect was significantly potentiated by pharmacological AMPK activation and mTOR inhibition. Exogenous NMN blocked both the activation of the AMPK pathway and the decrease in cell viability. Panc-1 cells expressing GFP-luciferase were orthotopically implanted on mice pancreas to test the in vivo effectiveness of STF-118804. Both STF-118804 and FK866 reduced tumor size after 21 days of treatment. Combinations of STF- 118804 with chemotherapeutic agents such as paclitaxel, gemcitabine, and etoposide showed an additive effect in decreasing cell viability and growth. In conclusion, our preclinical study shows that the NAMPT inhibitor STF-118804 reduced the growth of PDAC in vitro and in vivo and had an additive effect in combination with main current chemotherapeutic drugs.

KW - Metabolism

KW - NAD

KW - NAMPT

KW - Pancraetic cancer

KW - STF-11804

UR - http://www.scopus.com/inward/record.url?scp=85031502507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031502507&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.18841

DO - 10.18632/oncotarget.18841

M3 - Article

VL - 8

SP - 85054

EP - 85067

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 49

ER -